目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Company revenue analysis (Bottom-up approach)
2.2.1.2 Revenue share analysis
2.2.1.3 MnM repository analysis
2.2.1.4 Primary interviews
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES
3.1.2 ESTABLISHED MARKET LEADERS
3.1.3 CDMOS AND CROS

4 PREMIUM INSIGHTS
4.1 RADIOLIGAND THERAPY MARKET OVERVIEW
4.2 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT AND COUNTRY, 2025
4.3 RADIOLIGAND THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 RADIOLIGAND THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS
4.5 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.6 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT
4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE
4.8 REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing approvals and label expansion of RLT products
5.2.1.2 Manufacturing scale-up of Lu-177
5.2.1.3 Rising adoption of prostate-specific membrane antigen and somatostatin receptor PET imaging
5.2.1.4 Expanding reimbursement coverage
5.2.2 RESTRAINTS
5.2.2.1 Isotope supply scarcity
5.2.2.2 Stringent regulatory requirements
5.2.2.3 Logistical hurdles and half-life constraints
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in alpha therapies
5.2.3.2 Expansion of radioligand therapy into earlier-line and adjuvant settings
5.2.3.3 Combination regimens integrating radioligand therapy
5.2.4 CHALLENGES
5.2.4.1 Reactor outages and geopolitical risks
5.2.4.2 Growing competition from alternative modalities
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 INVESTMENT AND FUNDING SCENARIO
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Beta-emitting therapeutic radionuclides
5.8.1.2 Alpha-emitting therapeutic radionuclides
5.8.1.3 Targeting ligands
5.8.1.4 Monoclonal antibody-directed radiotherapeutics
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 SPECT/CT and PET/CT
5.8.2.2 Alternative isotopes
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Antibody drug conjugates
5.8.3.2 Bispecific antibodies
5.9 KEY CONFERENCES AND EVENTS, 2025-2027
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY ANALYSIS
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER'S FIVE FORCES ANALYSIS
5.11.1 BARGAINING POWER OF SUPPLIERS
5.11.2 BARGAINING POWER OF BUYERS
5.11.3 THREAT OF NEW ENTRANTS
5.11.4 THREAT OF SUBSTITUTES
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY STAKEHOLDERS AND BUYING PROCESS
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 MACROECONOMICS INDICATORS
5.13.1 HEALTHCARE EXPENDITURE TRENDS
5.13.2 GLOBAL CANCER BURDEN
5.14 PIPELINE ANALYSIS
5.15 UNMET NEEDS AND WHITE SPACES
5.16 IMPACT OF AI/GEN AI ON RADIOLIGAND THERAPY MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI IN RADIOLIGAND THERAPY APPLICATIONS
5.16.3 AI USE CASES
5.17 IMPACT OF 2025 US TARIFF
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 IMPACT ON COUNTRY/REGION
5.17.4.1 US
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.4.4 Rest of the World
5.17.5 IMPACT ON MANUFACTURING INDUSTRY

6 RADIOLIGAND THERAPY MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 LUTETIUM 177 VIPIVOTIDE TETRAXETAN
6.2.1 BROADER REGULATORY ACCEPTANCE AND EXPANDING PAYER COVERAGE TO AID GROWTH
6.3 LUTETIUM-177 DOTATATE
6.3.1 INCREASING RECOGNITION OF LUTETIUM-177 DOTATATE IN TREATING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO BOOST MARKET
6.4 RADIUM-223 DICHLORIDE
6.4.1 INCREASING ADOPTION OF RADIUM-223 DICHLORIDE IN EMERGING MARKETS TO STIMULATE GROWTH
6.5 LU-177 PNT2002
6.5.1 STRONG PHASE III CLINICAL VALIDATION AND STRATEGIC COMMERCIALIZATION PARTNERSHIPS TO SPUR GROWH
6.6 225AC-PSMA-617
6.6.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO BOLSTER GROWTH
6.7 FPI-2265
6.7.1 EARLY RESPONSE DATA AND SAFETY REASSURANCE TO AMPLIFY GROWTH
6.8 I-131-1095
6.8.1 FAVORABLE DOSIMETRY AND SAFETY PROFILES TO SUSTAIN GROWTH
6.9 TLX591
6.9.1 SIMPLIFIED DOSING REGIMEN AND FAVORABLE TOLERABILITY TO DRIVE MARKET
6.10 ALPHAMEDIX ( 212PB-DOTAMTATE)
6.10.1 ROBUST EARLY-PHASE EFFICACY AND STRONG COMMERCIALIZATION TO SUPPORT GROWTH
6.11 67CU-SAR-BISPSMA
6.11.1 ENHANCED LESION UPTAKE & RETENTION AND FAVORABLE TOLERABILITY PROFILE TO FOSTER GROWTH
6.12 OTHER PRODUCTS

7 RADIOLIGAND THERAPY MARKET, BY TARGET
7.1 INTRODUCTION
7.2 PROSTATE-SPECIFIC MEMBRANE ANTIGEN
7.2.1 STRONG BIOLOGICAL RATIONALE, ROBUST CLINICAL OUTCOMES, AND RAPID SCALING OF GLOBAL SUPPLY CHAINS TO PROMOTE GROWTH
7.3 SOMATOSTATIN RECEPTOR
7.3.1 PROVEN EFFICACY IN TREATING NEUROENDOCRINE TUMORS TO EXPEDITE GROWTH
7.4 OTHER TARGETS

8 RADIOLIGAND THERAPY MARKET, BY INDICATION
8.1 INTRODUCTION
8.2 PROSTATE CANCER
8.2.1 EXPANDING TREATMENT POPULATIONS AND CLINICAL VALIDATION TO ENCOURAGE GROWTH
8.3 NEUROENDOCRINE TUMORS
8.3.1 REGULATORY ADVANCEMENTS AND STRATEGIC INDUSTRY MOVES TO FACILITATE GROWTH
8.4 OTHER INDICATIONS

9 RADIOLIGAND THERAPY MARKET, BY END USER
9.1 INTRODUCTION
9.2 TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS
9.2.1 ADVANCED TREATMENT DELIVERY AND CLINICAL TRIAL CAPABILITIES TO CONTRIBUTE TO GROWTH
9.3 SPECIALIZED NUCLEAR MEDICINE CENTERS
9.3.1 HIGHLY TRAINED PERSONNEL AND TARGETED FACILITIES TO ACCELERATE GROWTH
9.4 OTHER END USERS

10 RADIOLIGAND THERAPY MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Robust ecosystem of biotech innovation and strong academic-industry collaboration to spur growth.
10.2.3 CANADA
10.2.3.1 Growing clinical trial momentum to drive market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Strong clinical advancements and active industry partnerships to foster growth.
10.3.3 UK
10.3.3.1 Growing efforts for decentralized access and innovations to boost market
10.3.4 FRANCE
10.3.4.1 Strong nuclear medicine manufacturing and isotope supply foundation to bolster growth
10.3.5 ITALY
10.3.5.1 Rising preclinical exploration and early discovery stages to stimulate growth
10.3.6 SPAIN
10.3.6.1 Established nuclear-medicine departments and authorized radiopharmacy frameworks to aid growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Favorable regulatory reforms and expanding hospital-based nuclear medicine capabilities to amplify growth
10.4.3 JAPAN
10.4.3.1 Academic excellence, manufacturing expansion, and supportive regulation to contribute to growth
10.4.4 INDIA
10.4.4.1 Lower trial costs and skilled medical professionals to accelerate growth
10.4.5 SOUTH KOREA
10.4.5.1 Growing emphasis on nuclear medicine innovation to propel market
10.4.6 AUSTRALIA
10.4.6.1 Need to maintain high standards of quality, compliance, and innovation to facilitate growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Favorable educational initiatives and expanding biopharma infrastructure to promote growth
10.5.3 MEXICO
10.5.3.1 Growing cyclotron capacity to fuel market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
10.6.2 GCC COUNTRIES
10.6.3 SAUDI ARABIA
10.6.3.1 Growing initiatives for healthcare and life sciences sectors to drive market
10.6.4 UAE
10.6.4.1 Emerging biotechnology sector to intensify growth
10.6.5 REST OF GCC COUNTRIES
10.6.6 REST OF MIDDLE EAST
10.7 AFRICA
10.7.1 ENHANCED CLINICAL TRIAL ECOSYSTEM AND REGULATORY REFORMS TO AID GROWTH
10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.4 REVENUE ANALYSIS, 2028-2030
11.5 MARKET SHARE ANALYSIS, 2030
11.6 COMPANY VALUATION AND FINANCIAL METRICS
11.7 BRAND/PRODUCT COMPARISON
11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.8.1 STARS
11.8.2 EMERGING LEADERS
11.8.3 PERVASIVE PLAYERS
11.8.4 PARTICIPANTS
11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.8.5.1 Region footprint
11.8.5.2 Target footprint
11.8.5.3 Indication footprint
11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.9.1 PROGRESSIVE COMPANIES
11.9.2 RESPONSIVE COMPANIES
11.9.3 DYNAMIC COMPANIES
11.9.4 STARTING BLOCKS
11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.9.5.1 Detailed list of key startups/SMEs
11.9.5.2 Competitive benchmarking of key startups/SMEs
11.10 COMPETITIVE SCENARIO
11.10.1 PRODUCT LAUNCHES AND APPROVALS
11.10.2 DEALS
11.10.3 EXPANSIONS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 NOVARTIS AG
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Products in pipeline
12.1.1.4 Recent developments
12.1.1.4.1 Product launches and approvals
12.1.1.4.2 Deals
12.1.1.4.3 Expansions
12.1.1.5 MnM view
12.1.1.5.1 Key strengths
12.1.1.5.2 Strategic choices
12.1.1.5.3 Weaknesses and competitive threats
12.1.2 BAYER AG
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.2.1 Deals
12.1.2.2.2 Other developments
12.1.2.3 MnM view
12.1.2.3.1 Key strengths
12.1.2.3.2 Strategic choices
12.1.2.3.3 Weaknesses and competitive threats
12.1.3 CURIUM US LLC
12.1.3.1 Business overview
12.1.3.2 Products in pipeline
12.1.3.3 Recent developments
12.1.3.3.1 Deals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 ELI LILLY AND COMPANY
12.1.4.1 Business overview
12.1.4.2 Products in pipeline
12.1.4.3 Recent developments
12.1.4.3.1 Product launches and approvals
12.1.4.3.2 Deals
12.1.4.4 MnM view
12.1.4.4.1 Key strengths
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses and competitive threats
12.1.5 ASTRAZENECA
12.1.5.1 Business overview
12.1.5.2 Products in pipeline
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses and competitive threats
12.1.6 PROGENICS PHARMACEUTICALS INC. (LANTHEUS)
12.1.6.1 Business overview
12.1.6.2 Products in pipeline
12.1.6.3 Recent developments
12.1.6.3.1 Deals
12.1.7 ARICEUM THERAPEUTICS
12.1.7.1 Products in pipeline
12.1.7.2 Recent developments
12.1.7.2.1 Deals
12.1.8 TELIX PHARMACEUTICALS
12.1.8.1 Business overview
12.1.8.2 Products in pipeline
12.1.8.3 Recent developments
12.1.8.3.1 Deals
12.1.8.3.2 Expansions
12.1.8.3.3 Other developments
12.1.9 ITM ISOTOPE TECHNOLOGIES
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Deals
12.1.9.3.2 Expansions
12.1.10 CONVERGENT THERAPEUTICS, INC.
12.1.10.1 Business overview
12.1.10.2 Products in pipeline
12.1.10.3 Recent developments
12.1.10.3.1 Product launches and approvals
12.1.10.3.2 Deals
12.1.11 ORANO SA
12.1.11.1 Business overview
12.1.11.2 Products in pipeline
12.1.11.3 Recent developments
12.1.11.3.1 Deals
12.1.11.3.2 Expansions
12.1.12 ACTINIUM PHARMACEUTICALS, INC.
12.1.12.1 Business overview
12.1.12.2 Products in pipeline
12.1.12.3 Recent developments
12.1.12.3.1 Product launches and approvals
12.1.12.3.2 Deals
12.1.13 PERSPECTIVE THERAPEUTICS, INC.
12.1.13.1 Business overview
12.1.13.2 Products in pipeline
12.1.13.3 Recent developments
12.1.13.3.1 Deals
12.1.14 CLARITY PHARMACEUTICALS
12.1.14.1 Business overview
12.1.14.2 Products in pipeline
12.1.14.3 Recent developments
12.1.14.3.1 Deals
12.1.14.3.2 Other developments
12.1.15 RADIOPHARM THERANOSTICS LTD.
12.1.15.1 Business overview
12.1.15.2 Products in pipeline
12.1.15.3 Recent developments
12.1.15.3.1 Deals
12.2 OTHER PLAYERS
12.2.1 ALPHA 9 ONCOLOGY
12.2.2 RATIO THERAPEUTICS
12.2.3 NORIA THERAPEUTICS
12.2.4 PRECIRIX
12.2.5 SOFIE
12.2.6 ECKERT & ZIEGLER RADIOPHARMA
12.2.7 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
12.2.8 IRE- IRE ELIT
12.2.9 BWXT MEDICAL LTD.
12.2.10 NTP RADIOISOTOPES

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS